By
From the Center for Immunology, Departments of Pathology and Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To define immune mechanisms that regulate chronic and latent herpesvirus infection, we analyzed the role of interferon (IFN-
) during murine cytomegalovirus (MCMV) infection. Lethality studies demonstrated a net protective role for IFN-
, independent of IFN-
/
, during
acute MCMV infection. Mice lacking the IFN-
receptor (IFN-
R
/
) developed and maintained striking chronic aortic inflammation. Arteritis was associated with inclusion bodies and
MCMV antigen in the aortic media. To understand how lack of IFN-
responses could lead to
chronic vascular disease, we evaluated the role of IFN-
in MCMV latency. MCMV-infected
IFN-
R
/
mice shed preformed infectious MCMV in spleen, peritoneal exudate cells, and
salivary gland for up to 6 mo after infection, whereas the majority of congenic control animals
cleared chronic productive infection. However, the IFN-
R was not required for establishment of latency. Using an in vitro explant reactivation model, we showed that IFN-
reversibly inhibited MCMV reactivation from latency. This was at least partly explained by IFN-
-
mediated blockade of growth of low levels of MCMV in tissue explants. These in vivo and in
vitro data suggest that IFN-
regulation of reactivation from latency contributes to control of
chronic vascular disease caused by MCMV. These studies are the first to demonstrate that a
component of the immune system (IFN-
) is necessary to regulate MCMV-associated elastic
arteritis and latency in vivo and reactivation of a herpesvirus from latency in vitro. This provides a new model for analysis of the interrelationships among herpesvirus latency, the immune
system, and chronic disease of the great vessels.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Human cytomegalovirus (HCMV)1 establishes a chronic infection in normal hosts, characterized by latency and intermittent shedding of infectious virus. HCMV causes severe reactivation disease in situations of immunocompromise, and is a frequent cause of morbidity and mortality in transplant and AIDS patients. The specific components of the immune system that are responsible for preventing reactivation disease have not been identified. Reactivation disease in humans involves multiple tissues, including the retina, liver, lung, and gastrointestinal tract. In apparently immunocompetent hosts, CMV has been implicated in the genesis of atherosclerosis (1), rapidly progressive coronary artery disease and endothelialitis in cardiac transplant patients (4), coronary restenosis after angioplasty (8, 9), and inflammatory aortic diseases (10, 11). Although these studies suggest a role for HCMV in human vascular disease, this is an area of considerable controversy (12). Since MCMV can cause aortic inflammation in weanling mice (16), we focused on the great vessels as possible targets for chronic MCMV disease.
The role of the innate and adaptive immune systems in
controlling acute MCMV infection has been well characterized. CD8 T cells are primary effector cells in clearance
of MCMV during acute infection (17, 18). However,
MCMV replication can be controlled by CD4 T cells
when CD8 T cells are depleted (19), and CD4 T cells are
required to clear virus from the salivary gland (18). NK
cells play a significant role in the control of acute infection with MCMV, and at least one mechanism for NK cell protection is secretion of IFN- (20). IFN-
has a number
of functions that probably play a role in controlling acute
MCMV infection. These include activation of macrophages
during MCMV infection (21), enhancement of MHC class
I-dependent antigen presentation by infected cells to CD8
T cells (23), and inhibition of lytic MCMV replication and
gene expression (21, 24, 25). Administration of recombinant IFN-
can protect against lethal infection (26), and administration of anti-IFN-
can both decrease the effectiveness of anti-MCMV CD8 and CD4 T cells (23, 27) and
increase viral titers in visceral organs (21, 27). CD4 T cells
specific for the HCMV immediate early 1 protein produce
cytokines including IFN-
and TNF-
on antigenic stimulation, which inhibit viral replication in MRC5 cells (28).
Although these studies all argue for a protective role for
IFN-
, other studies in both rat CMV and HCMV have argued that IFN-
is required to generate productive infection of macrophages and efficient replication in vivo (29,
30). These results raise the question of whether the net effect of endogenous IFN-
is protective.
After a period of persistent productive infection in the salivary gland, MCMV establishes a predominantly latent infection in immunocompetent mice (31, 32). Latency is characterized by the presence of viral genome in the absence of
preformed infectious virus combined with the capacity to
reactivate either in vivo or in vitro from tissue explants. The
extent to which the immune system regulates and controls
latency is not fully understood. It is thought that the immune
system regulates latency because immunosuppression results
in reactivation of lytic MCMV (33). Reactivation is a
multistep process that may be divided into two phases: cellular reactivation and subsequent growth of virus. Cellular reactivation probably results from a shift from latent to lytic
gene expression; nothing is known about whether or how the immune system alters this process. Cellular reactivation is followed by growth of reactivated virus to levels that cause
disease or are experimentally detectable. The mechanisms
responsible for controlling viral replication after cellular reactivation are also incompletely defined, although the immune
system is likely to play a role at this step in reactivation. For
example, antibody has been shown to limit dissemination of
MCMV after reactivation (36). IFN- is a good candidate in
regulating growth of reactivated MCMV given its importance for clearing persistent productive infection of the
salivary gland (27).
In this study we first demonstrate that the net effect of
endogenous IFN- is protective during acute infection in
vivo. We then show that IFN-
plays an important role
during chronic MCMV infection in vivo and during reactivation in vitro. In the course of these studies we have defined a novel role for IFN-
in regulating chronic vascular
pathology due to MCMV.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Viruses and Viral Assays.
MCMV Smith strain was obtained from the American Type Culture Collection (no. VR-194, Lot 10; Rockville, MD). Tissue culture-passaged MCMV (tcMCMV) and salivary gland MCMV (sgMCMV) were generated as described previously (21, 31). All media were prepared as described previously (37). Murine embryonic fibroblasts (MEFs) were prepared and used during initial passaging or thawed from frozen stocks (31). All MEFs were used before passage 4. To detect and quantitate MCMV genome, nested PCR detecting sequences of the MCMV immediate early 1 gene were performed on DNA from bone marrow cells as described previously (31). This nested PCR assay reproducibly detects one copy of target plasmid (31, 37). MCMV sequences are quantitatively recovered in tissue DNA preparations (31). Herpes simplex virus (HSV) was grown and titered as described previously (21). The myocarditic reovirus serotype 3 8B was grown and titered as described previously (38).Mice, Mouse Infections, and Tissue Harvests.
129/Sv mice and mice with null mutations in the IFN-Pathology and Immunohistochemistry.
To analyze aortic pathology, the heart, lungs and great vessels were resected en bloc after death and processed as described elsewhere (40). In brief, serial sections from the posterior of the heart through the thymus were prepared and stained with hematoxylin and eosin and then read blindly for aortic pathology by either H.W. Virgin or A.J. Dal Canto. Samples were scored as positive if evidence of arteritis in the aorta or pulmonary artery was observed. Since arteritis most commonly involved the base of the aorta, samples were called negative only if a clear view of the base of the aorta was available; samples were excluded if the base of the aorta was not visible. Murine polyclonal antibody to MCMV was prepared as follows. BALB/c mice were infected with 105 PFU tcMCMV. Salivary glands were harvested at 20 d after infection, homogenized in medium lacking FCS, and titered by plaque assay. BALB/c mice were infected with 104 PFU of this stock. Mice were bled through the retroorbital plexus at 1, 2, and 3 mo after additional boosts with 1.2 × 105 PFU of sgMCMV. This approach was taken to minimize immunization with FCS in tissue culture preparations of virus. Immunization with murine cellular antigens was avoided by selection of BALB background mice for both preparation of virus and serum generation. Immunohistochemical staining was performed as described previously (40) except that the murine polyclonal antibody to MCMV was diluted 1:1000. Preimmune serum was also used at a 1:1000 dilution as a negative control. Horseradish peroxidase (HRP)-conjugated donkey anti- mouse secondary antibody (Jackson Immunoresearch Labs., West Grove, PA) was used at 1:1000. Tyramide signal amplification (NEN Life Science Products, Boson, MA) was performed and HRP activity was localized as previously described (40).MCMV Reactivation from Explanted Organs and Bone Marrow.
Spleens or lungs from 8-13 latently infected BALB/c or C57BL/ 6 mice were pooled, minced, homogenized using a Tenbroeck Tissue Homogenizer (Bellco, Vineland, NJ), and plated evenly into 12 six-well plates (Falcon, Franklin Lakes, NJ). An aliquot (0.3-0.5 spleen or lung equivalents) was diluted, sonicated, and cocultured with MEFs to rule out the presence of preformed infectious virus in pooled spleen and lung explants (see above). Explants were cultured in the presence of mock IFN (prepared by Lee Biomolecular, San Diego, CA, in the same manner as their IFN preparations, except that it is mock induced), 100 U/ml IFN-
|
|
Statistical Methods.
Statistical analysis was carried out through the Division of Biostatistics at Washington University School of Medicine. The data were analyzed using the SAS procedure PHREG, which performs regression analysis of survival data based on the Cox proportional hazards model. This model was particularly relevant to these data as it takes into account the censoring of the day of death or killing. The dependent variables used to analyze lethality data (Fig. 1) were day of death censored by whether or not the animal died on its own. Cox proportional hazards models were developed to first test all of the strains against the control (129 or B6) with dose and sex as covariates. Then models were developed to pairwise compare each experimental strain against the others, still using dose and sex as covariates. Mouse strain was a significant predictor of outcome independent of viral dose or sex (see text). The arteritis data (Table 1) were also analyzed using a Cox proportional hazards model, comparing the IFN-
|
|
|
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Control congenic mice and mice with various null mutations influencing IFN responsiveness were challenged with varying doses of MCMV and followed for mortality (Fig. 1). Sharp
changes in mortality observed with small changes in viral
dose have been previously reported and necessitated the use
of large numbers of age-matched mice across many experiments to obtain clear data (42, 43). We have evaluated 416 mice in the course of these experiments. We aged mice at
least 2 mo before challenge to minimize the impact of large
changes in susceptibility to lethal MCMV infection that
occur over the first weeks of life (our unpublished data). The LD50's for IFN-R
/
and IFN-
/
mice were approximately five- and fourfold lower, respectively, than for
congenic (129 and C57BL/6) control mice (P <0.02; P < 0.005). IFN-
/
might compensate for some effects of
IFN-
since both can inhibit MCMV replication in vivo
and in vitro (21, 24, 25). We therefore evaluated IFN-
/
R
/
mice and found that the LD50 for IFN-
/
R
/
mice was 800-fold lower than for control 129 mice (P
<0.0002). To determine the importance of IFN-
in the
absence of IFN-
/
responses, we compared IFN-
/
R
/
and IFN-
/
/
R
/
mice. As few as 10 PFU of MCMV
killed 100% of IFN-
/
/
R
/
mice, and thus an LD50
could not be determined. However, the LD50 for IFN-
/
/
R
/
mice was at least 40-fold lower than for IFN-
/
R
/
mice (P < 0.0001). These data demonstrate that
IFN-
plays a net protective role in MCMV infection, and
that IFN-
effects are not completely redundant with those
of IFN-
/
.
Given the importance of IFN- to regulating acute
MCMV infection, we examined the course of chronic
MCMV infection in IFN-
R
/
mice given a dose that
most would survive for at least 21 d of infection (Fig. 1; 1-5 × 104 PFU). Because MCMV can cause aortic disease in
newborn immunocompetent mice (16), we examined the
aorta for signs of pathology over the first 154 d of infection
(Table 1). Early after infection (days 28-56), lesions of the
aorta were seen in 4 out of 10 normal 129 and 5 out of 6 IFN-
R
/
mice. Interestingly, after day 84 aortic lesions
were not seen in 129 mice (0 out of 24 mice; Table 1). In
contrast, most IFN-
R
/
mice had significant lesions as
late as 154 d after infection (15 out of 27 mice; Table 1
and Fig. 2). This difference is statistically significant, with P
<0.0033. These lesions involved all layers (intima, media,
and adventitia) of the vessels (Figs. 2, C and D, and 3 A). A
prominent inflammatory infiltrate consisting primarily of
mononuclear cells was observed (Figs. 2 D and 3 A). Cytomegalic inclusion bodies were seen within cells in the
aortic media (Fig. 3 B). Immunohistochemistry revealed
MCMV antigens in the media of affected aortas (Fig. 3, C
and D). Cells in the aortic media containing inclusions and
MCMV antigen were morphologically consistent with
smooth muscle cells. We have previously published that arteritis is not seen in mock infected IFN-
R
/
mice observed for 6 to 15 wk (40). Furthermore mice infected with
either a myocarditic reovirus reassortant (8B) or HSV failed to show lesions 84 d after infection (Table 1). At this time IFN-
R
/
mice infected with MCMV showed aortic pathology. These experiments demonstrate that MCMV
causes chronic vascular pathology in IFN-
R
/
mice, and
illustrate a tropism for cells of the aortic media during
chronic infection.
|
|
Aortic pathology in IFN-R
/
mice seemed likely to be due to an important role
of IFN-
in controlling chronic MCMV infection. 29 IFN-
R
/
mice and 28 wild-type 129 mice were therefore evaluated for the presence of preformed infectious virus at times during which MCMV transitions from a
chronic productive salivary gland infection to a latent infection in a majority of immunocompetent mice (Table 2).
Spleen, salivary gland, PECs, and bone marrow cells were sonicated and cultured on MEFs to detect low levels of
preformed infectious virus. IFN-
R
/
mice were productively infected in at least one of the tissues tested out to 180 d
after infection. Only one of four IFN-
R
/
mice survived
to the 180 d time point. Although preformed infectious virus was detected in some congenic control 129 mice, the
majority established a latent infection in the absence of persistent productive infection as has been shown for BALB/c
mice (31, 32). Differences between IFN-
R
/
and 129 mice are statistically significant for total mice shedding (P < 0.009), mice shedding in the spleen (P <0.01) and salivary gland (P <0.009). The presence of low levels of preformed MCMV in IFN-
R
/
mice in spleen and PECs
demonstrates that IFN-
regulates chronic infection with
MCMV in several locations in addition to salivary gland (27).
Since we detected chronic productive infection in several
tissues in IFN-R
/
mice, we were interested in assessing
whether a latent infection could be established in the absence of IFN-
responsiveness. Of the tissues tested for
chronic productive MCMV infection in IFN-
R
/
mice,
only bone marrow consistently lacked detectable preformed infectious MCMV. Bone marrow cells (between
10 and 25 × 106 per mouse) were tested from 22 IFN-
R
/
mice and contained no preformed infectious virus as
detected by coculture with MEFs (six independent experiments). Since coculture with MEFs regularly detects 5 PFU
of MCMV, these experiments showed that there was <1
PFU of MCMV per 2-5 × 106 bone marrow cells from
IFN-
R
/
mice. To determine if the lack of infectious
MCMV in bone marrow cells reflected a lack of MCMV
infection in the bone marrow of IFN-
R
/
mice, DNA
was isolated from bone marrow cells and PCR was used to
quantitate the level of viral genome (31). Dilutions of
DNA from 129 and IFN-
R
/
mice revealed that the
amount of viral genome in DNA samples was similar (Fig.
4). The presence of viral genome in the absence of productive infection suggests that MCMV establishes either a latent or abortive infection in the bone marrow of IFN-
R
/
mice. To demonstrate that the viral genome that we detected was due to latent infection, bone marrow cells were
cultured in vitro to induce reactivation. 8 out of 19 cultures of IFN-
R
/
bone marrow reactivated MCMV. 2 out of 18 cultures of wild-type 129 bone marrow reactivated MCMV. The presence of viral genome in bone marrow cells, and the capacity to reactive MCMV from bone marrow cultures demonstrates that IFN-
is not required
to establish latency in the bone marrow.
|
Since latency can be established
in the absence of IFN- responsiveness, we examined the
hypothesis that IFN-
controls reactivation from MCMV
latency. We took advantage of an in vitro assay in which latently infected spleen (31, 33, 44, 45) or lung explants reactivate at high frequency upon culture in vitro. Explants
were cultured in the presence of media alone, media plus
mock IFN, or media with 100 U/ml IFN-
, IFN-
, or
IFN-
. Explant supernatant was sampled every 3-4 d for
64-116 d and tested for infectious virus by culture on
MEFs (Fig. 5, A and B). Explants were tested for chronic
productive MCMV infection present at the time of explantation by culturing a sonicated aliquot with MEFs (see Materials and Methods). These control cultures were consistently negative. Although 100% of lung explants that were
treated with media alone or with mock IFN reactivated by
day 35, only 12.5-15% of explant cultures treated with
IFN-
reactivated (Fig. 5 A). Explants treated with IFN-
or IFN-
showed an intermediate block to reactivation.
Similar results were seen with spleen explants, although the
frequency of reactivation is lower (Fig. 5 B). We considered several explanations for the lack of detection of reactivated MCMV in explants treated with IFN-
. IFN treatment might prevent reactivation of MCMV by killing
latently infected cells. To assess this possibility, IFN treatments were withdrawn on day 35 for lung explants and day 38 for spleen explants. In some explants, IFN-
treatment
was continued. After cytokine removal, an additional 9 out
of 21 lung explant cultures previously treated with IFN-
reactivated, suggesting that the blockade of reactivation induced by IFN-
is at least partially reversible (Fig. 5 A).
Cultures that continued to receive IFN-
during this time
did not reactivate. Similar results were seen in spleen explant cultures (Fig. 5 B). This reversibility of IFN-
effect
argues against IFN-
-induced killing of cells containing latent virus as a mechanism of reactivation blockade. Another explanation for our lack of detection of MCMV reactivation in these treated explants may be that the IFNs
carried over from explant cultures decrease our ability to
detect infectious MCMV in MEF cultures. However, 5 PFU
of MCMV added to media from IFN-
-treated explants
was detected on MEF monolayers in 18 out of 18 times. These data were consistent with a direct blockade of MCMV
reactivation by IFN-
treatment.
IFN- could inhibit reactivation by blocking either cellular
reactivation or growth of reactivated virus. Since the molecular nature of MCMV latency is unknown, we could
not examine an effect of IFN-
on cellular reactivation directly. However, we hypothesized that IFN-
could block
reactivation in explant cultures by blocking the growth of
small amounts of virus released during cellular reactivation.
We therefore made lung and spleen explant cultures using
organs from uninfected mice and treated them with IFNs
as for explants from latently infected organs. To mimic a
reactivation event, either 10 or 50 PFU of MCMV was
added on day 12, and the explants were observed for production of MCMV for the ensuing 39 d (Fig. 6). The
number of wells productively infected with MCMV was
decreased by IFN-
treatment in both spleen and lung explants given either 10 or 50 PFU (Fig. 6). This shows that
IFN-
can block productive infection with low levels of
MCMV. IFN-
had a similar effect when an inoculum of
10 PFU was used, but was less effective than IFN-
when
an inoculum of 50 PFU was used. These data demonstrate
that under certain conditions of infection, IFN-
can effectively prevent growth of low levels of MCMV in explant
cultures. This blockade could account for the inhibition of
reactivation we observed in explant cultures from latently infected mice (Fig. 5). The lack of IFN-
-mediated inhibition of outgrowth of reactivated virus could contribute to
the presence of preformed infectious MCMV in IFN-
R
/
mice detected during chronic infection (Table 2).
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The experiments reported here demonstrate the following
important points: (a) IFN- regulates chronic infection with
MCMV in multiple tissues in addition to the salivary gland
(27); (b) IFN-
is not required for establishment of MCMV
latency; (c) IFN-
can reversibly block reactivation from
latency in an in vitro model; (d) one mechanism by which
IFN-
might regulate chronic MCMV infection is blockade
of the growth of low levels of infectious virus; and (e) one
consequence of the absence of IFN-
responsiveness is
chronic inflammatory disease in the large elastic arteries. Previous work has shown that IFN-
is present for prolonged
times in trigeminal ganglia latently infected with the
-herpesvirus HSV (46, 47), suggesting IFN-
as a candidate for regulating chronic HSV infection. IFN-
plays a role in chronic
infection with
-herpesviruses, as is illustrated by the severe
chronic elastic arteritis seen in IFN-
nonresponsive mice infected by the murine
-herpesvirus 68 (
HV68; reference
40). Experiments presented here provide the first evidence
that IFN-
regulates chronic infection with a
-herpesvirus,
MCMV, potentially by controlling reactivation from latency.
In addition, lack of IFN-
regulation of MCMV infection
has significant pathologic consequences for the host. The fact
that lack of response to a single cytokine results in severe
MCMV-associated pathology suggests that penetrance and
severity of disease during chronic herpesvirus infection is regulated by relatively subtle changes in host defense.
We found that IFN-
is important for controlling chronic infection with MCMV,
but was not essential for the establishment of latency in bone
marrow cells. It was possible that events during early stages
of infection set the stage for chronic productive infection
(e.g., by altering the cells infected or the viral load in specific
cells or tissues). However, IFN-
was effective at preventing
the reactivation of latent MCMV from tissue explants, suggesting that IFN-
has significant effects during chronic infection in addition to any effects of IFN-
during acute infection. Notably, the effect of IFN-
lasted for up to 116 d,
and was reversible after 30-40 d of culture. These results argue that IFN-
is very effective in this role, and that IFN-
does not act by killing all latent cells. IFN-
and IFN-
were less effective. This, combined with the fact that IFN-
has a role during acute infection that is not redundant to the
effects of IFN-
and IFN-
(Fig. 1), argues strongly that
IFN-
is a key regulator of all phases of MCMV infection.
The effect of IFN- on reactivation from tissue explants
could be due to effects on either cellular reactivation or
growth of virus in explant cultures after cellular reactivation has occurred. We found that IFN-
can completely
block the growth of low levels of MCMV in explant cultures. This effect was significant enough that it could account entirely for the effects of IFN-
on reactivation from
latent tissue explants. This being the case, we cannot address the possibility that IFN-
might have a role in regulating cellular reactivation. The mechanism by which IFN-
works to prevent MCMV growth is controversial. Several
studies have shown that IFN-
can decrease viral yields
(21, 24, 25), but studies demonstrating an effective block
on replication of low levels of infectious MCMV have not
previously been reported. Some studies have suggested a role
for IFN-
in regulating transcription of the MCMV immediate early genes, whereas others have suggested a role for
IFN-
later in the lytic replication cycle (24, 25). Further
studies will be required to define these mechanism(s) at the
molecular level, and to understand how they might contribute to prolonged blockade of viral growth.
It is interesting that MCMV and HCMV both have
mechanisms to block the signaling of IFN- in infected
cells. MCMV inhibits IFN-
induction of MHC gene expression at a step downstream from STAT (signal transducer and activator of transcription)-1 phosphorylation and
nuclear translocation (48). HCMV inhibits IFN-
signaling in infected cells by altering the turnover of Janus (JAK)
family kinases required for IFN-
action (49). Thus, both
the viruses have developed countermeasures that combat
the effects of IFN-
in infected cells. This creates an interesting balance between cytokine secretion and effectiveness
in vivo, and virus-encoded anticytokine actions. It is likely
that this critical balance defines the outcome of chronic
CMV infection. The capacity of HCMV to inhibit IFN-
signaling may explain the lack of effectiveness of IFN-
in
macrophages treated with IFN-
after infection (30).
The source of IFN- during chronic infection has not
been determined. Since IFN-
is important in both the
adaptive (both CD4- and CD8-mediated) and the innate
(NK cell-mediated) responses to MCMV infection, future
studies will have to assess the role of all three of these lymphocyte subsets as IFN-
producers during chronic infection. Since CD8 T cell-mediated secondary vaccine responses do not require IFN-
(42), we favor the hypothesis that CD4 T cells or NK cells are important during chronic
infection. This would be consistent with the proven role
for CD4 T cells and IFN-
in controlling persistent productive infection in the salivary gland (18, 27).
In this study, we confirmed that MCMV infects the great elastic arteries (16),
and demonstrated for the first time that in the absence of
the IFN- receptor MCMV causes chronic vascular pathology even in adult mice. It was notable that lack of IFN-
responsiveness was not a prerequisite for MCMV induction
of vascular pathology. Thus, normal mice showed signs of
disease early after infection. However, IFN-
R
/
mice
maintained lesions for much longer than normal mice, suggesting that IFN-
is critical for controlling infection in the
large elastic arteries. This is remarkably parallel to our studies
in mice infected with
HV68.
HV68 causes severe elastic
arteritis in IFN-
R
/
mice (40). The fact that MCMV and
HV68 are quite distinct in primary sequence (50, 51)
but cause disease of the elastic arteries in similar immunodeficient mice argues for the nature of the interaction between the tissue (elastic arteries) and IFN-
as the critical
determinant of virus induced vasculitis rather than specific
receptors or other proteins shared between MCMV and
HV68. Alternatively it is possible that both MCMV and
HV68 share specific IFN-
-sensitive interactions with
smooth muscle cells or other cells of the elastic arteries.
Latent MCMV has been identified in endothelial cells by
PCR in situ hybridization (52). It is tempting to speculate
that the lack of IFN- results in chronic vascular disease
because of a failure to control reactivation in endothelial
cells. An alternative hypothesis is that latently infected macrophages (37, 52) are the source of reactivating MCMV
that causes arteritis. IFN-
may also be essential for regulating vascular pathology via effects on the proliferation of
smooth muscle cells (53) or the development of foam cells,
which characterize atherosclerotic lesions (54).
In this report, we provide evidence that IFN- is a critical component in the regulation of chronic MCMV infection, without which severe pathologic consequences develop.
This may have implications for the role of herpesviruses in
vascular pathology. Explant studies suggest that IFN-
regulates MCMV latency by inhibiting reactivation from latency. One mechanism for this inhibition is the prevention of outgrowth of low levels of virus. Further studies are
needed to evaluate the mechanism of this block of reactivation, and to define the role of reactivation in the induction
of vascular pathology.
![]() |
Footnotes |
---|
Address correspondence to Herbert W. Virgin IV, Center for Immunology, Departments of Pathology and Molecular Microbiology, Washington University School of Medicine, Box 8118, 660 South Euclid Ave., St. Louis, MO 63110. Phone: 314-362-9223; Fax: 314-362-4096; E-mail: virgin{at}immunology.wustl.edu
Received for publication 30 March 1998 and in revised form 1 June 1998.
H.W. Virgin IV was supported by grant AI-39616 from the National Institute of Allergy and Infectious Diseases and the Monsanto-Searle Biomedical Agreement. A.J. Dal Canto was supported by National Institutes of Health (NIH) training grant 5T32 AI-07172 and NIH grant GM-07200. R.M. Presti was supported by NIH grant GM-07200. J.L. Pollock was supported by NIH training grant 5T32 AI-07163 and by the Lucille P. Markey Pathway at Washington University School of Medicine.We thank Avril Adelman at the Division of Biostatistics, Washington University, for performing statistical analyses. We also thank Dr. Sam Speck and Dr. David Leib and members of their laboratories for helpful commentary during the course of these studies.
Abbreviations used in this paper
HV68, murine
-herpesvirus 68;
HCMV, human cytomegalovirus;
HSV, herpes simplex virus;
MCMV, murine cytomegalovirus;
MEF, murine embryonic fibroblasts;
PEC, peritoneal exudate cell;
sgMCMV, salivary gland MCMV;
tcMCMV, tissue
culture-passaged MCMV.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Nieto, F.J.,
E. Adam,
P. Sorlie,
H. Farzadegan,
J.L. Melnick,
G.W. Comstock, and
M. Szklo.
1996.
Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis.
Circulation.
94:
922-927
|
2. | Sorlie, P.D., E. Adam, S.L. Melnick, A. Folsom, T. Skelton, L.E. Chambless, R. Barnes, and J.L. Melnick. 1994. Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC study. J. Med. Virol. 42: 33-37 [Medline]. |
3. | Melnick, J.L., E. Adam, and M.E. DeBakey. 1995. Cytomegalovirus and atherosclerosis. Bioessays. 17: 899-903 [Medline]. |
4. | Koskinen, P., K. Lemstrom, C. Bruggeman, I. Lautenschlager, and P. Hayry. 1994. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. Am. J. Pathol. 144: 41-50 [Abstract]. |
5. | Dummer, S., A. Lee, M.K. Breinig, R. Kormos, M. Ho, and B. Griffith. 1994. Investigation of cytomegalovirus infection as a risk factor for coronary atherosclerosis in the explanted hearts of patients undergoing heart transplantation. J. Med. Virol. 44: 305-309 [Medline]. |
6. | McDonald, K., T.S. Rector, E.A. Braunlin, S.H. Kubo, and M.T. Olivari. 1989. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am. J. Cardiol. 64: 359-362 [Medline]. |
7. | Grattan, M.T., C.E. Moreno-Cabral, V.A. Starnes, P.E. Oyer, E.B. Stinson, and N.E. Shumway. 1989. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA ( J. Am. Med. Assoc.). 261: 3561-3566 . [Abstract] |
8. | Speir, E., R. Modali, E.-S. Huang, M.B. Leon, F. Shawl, T. Finkel, and S.E. Epstein. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265: 391-394 [Medline]. |
9. |
Zhou, Y.F.,
M.B. Leon,
M.A. Waclawiw,
J.J. Popma,
Z.X. Yu,
T. Finkel, and
S.E. Epstein.
1996.
Association between
prior cytomegalovirus infection and the risk of restenosis after
coronary atherectomy.
N. Engl. J. Med.
335:
624-630
|
10. | Yonemitsu, Y., K. Nakagawa, S. Tanaka, R. Mori, K. Sugimachi, and K. Sueishi. 1996. In situ detection of frequent and active infection of human cytomegalovirus in inflammatory abdominal aortic aneurysms: possible pathogenic role in sustained chronic inflammatory reaction. Lab. Invest. 74: 723-736 [Medline]. |
11. | Tanaka, S., K. Komori, K. Okadome, K. Sugimachi, and R. Mori. 1994. Detection of active cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction. J. Vasc. Surg. 20: 235-243 [Medline]. |
12. | Adler, S.P., J.K. Hur, J.B. Wang, and G.W. Vetrovec. 1998. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J. Infect. Dis. 177: 209-212 [Medline]. |
13. | Gulizia, J.M., R. Kandolf, T.J. Kendall, S.L. Thieszen, J.E. Wilson, S.J. Radio, M.R. Costanzo, G.L. Winters, L.L. Miller, and B.M. McManus. 1995. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am. J. Pathol. 147: 461-475 [Abstract]. |
14. |
Kol, A.,
G. Sperti,
J. Shani,
N. Schulhoff,
W. van de Greef,
M.P. Landini,
M. La Placa,
A. Maseri, and
F. Crea.
1995.
Cytomegalovirus replication is not a cause of instability in
unstable angina.
Circulation.
91:
1910-1913
|
15. |
Pauletto, P.,
G. Pisoni,
R. Boschetto,
M. Zoleo,
A.C. Pessina, and
G. Palu.
1996.
Human cytomegalovirus and restenosis of
the internal carotid artery.
Stroke.
27:
1669-1671
|
16. | Dangler, C.A., S.E. Baker, M.K. Njenga, and S.H. Chia. 1995. Murine cytomegalovirus-associated arteritis. Vet. Pathol. 32: 127-133 [Abstract]. |
17. | Reddehase, M.J., W. Mutter, K. Munch, H.J. Buhring, and U.H. Koszinowski. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61: 3102-3108 [Medline]. |
18. | Jonjic, S., W. Mutter, F. Weiland, M.J. Reddehase, and U.H. Koszinowski. 1989. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J. Exp. Med. 169: 1199-1212 [Abstract]. |
19. | Jonjic, S., I. Pavic, P. Lucin, D. Rukavina, and U.H. Koszinowski. 1990. Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J. Virol. 64: 5457-5464 [Medline]. |
20. | Welsh, R.M., J.O. Brubaker, M. Vargas, Cortes, and C.L. O'Donnell. 1991. Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function. J. Exp. Med. 173: 1053-1063 [Abstract]. |
21. | Heise, M.T., and H.W. Virgin. 1995. The T cell independent role of IFN-gamma and TNF-alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infection. J. Virol. 69: 904-909 [Abstract]. |
22. |
Orange, J.S.,
B. Wang,
C. Terhorst, and
C.A. Biron.
1995.
Requirement for natural killer cell-produced interferon ![]() |
23. | Hengel, H., P. Lucin, S. Jonjic, T. Ruppert, and U.H. Koszinowski. 1994. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J. Virol. 68: 289-297 [Abstract]. |
24. | Gribaudo, G., S. Ravaglia, A. Caliendo, R. Cavallo, M. Gariglio, M.G. Martinotti, and S. Landolfo. 1993. Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription. Virology. 197: 303-311 [Medline]. |
25. | Lucin, P., S. Jonjic, M. Messerle, B. Polic, H. Hengel, and U.H. Koszinowski. 1994. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumor necrosis factor. J. Gen. Virol. 75: 101-110 [Abstract]. |
26. | Fennie, E.H., Y.S. Lie, M.A. Low, P. Gribling, and K.P. Anderson. 1988. Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon-gamma treatment. Antiviral Res. 10: 27-39 [Medline]. |
27. | Lucin, P., I. Pavic, B. Polic, S. Jonjic, and U.H. Koszinowski. 1992. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Virol. 66: 1977-1984 [Abstract]. |
28. | Davignon, J.-L., P. Castanie, J.A. Yorke, N. Gautier, D. Clement, and C. Davrinche. 1996. Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J. Virol. 70: 2162-2169 [Abstract]. |
29. | Haagmans, B.L., P.H. van der Meide, F.S. Stals, A.J. van den Eertwegh, E. Claassen, C.A. Bruggeman, M.C. Horzinek, and V.E. Schijns. 1994. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon. J. Virol. 68: 2305-2312 [Abstract]. |
30. |
Soderberg-Naucler, C.,
K.N. Fish, and
J.A. Nelson.
1997.
Interferon-gamma and tumor necrosis factor ![]() |
31. | Pollock, J.L., and H.W. Virgin. 1995. Latency, without persistence, of murine cytomegalovirus in spleen and kidney. J. Virol. 69: 1762-1768 [Abstract]. |
32. | Kurz, S., H.P. Steffens, A. Mayer, J.R. Harris, and M.J. Reddehase. 1997. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J. Virol. 71: 2980-2987 [Abstract]. |
33. | Mayo, D., J.A. Armstrong, and M. Ho. 1978. Activation of latent murine cytomegalovirus infection: cocultivation, cell transfer, and the effect of immunosuppression. J. Infect. Dis. 138: 890-896 [Medline]. |
34. | Mayo, D.R., J.A. Armstrong, and M. Ho. 1977. Reactivation of murine cytomegalovirus by cyclophosphamide. Nature. 267: 721-723 [Medline]. |
35. | Balthesen, M., M. Messerle, and M.J. Reddehase. 1993. Lungs are a major organ site of cytomegalovirus latency and recurrence. J. Virol. 67: 5360-5366 [Abstract]. |
36. | Jonjic, S., I. Pavic, B. Polic, I. Crnkovic, P. Lucin, and U.H. Koszinowski. 1994. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179: 1713-1717 [Abstract]. |
37. | Pollock, J.L., R.M. Presti, S. Paetzold, and H.W. Virgin. 1997. Latent murine cytomegalovirus infection in macrophages. Virology. 227: 168-179 [Medline]. |
38. | Sherry, B., X.-Y. Li, K.L. Tyler, J.M. Cullen, and H.W. Virgin. 1993. Lymphocytes protect against and are not required for reovirus induced myocarditis. J. Virol. 67: 6119-6124 [Abstract]. |
39. | Muller, U., S. Steinhoff, L.F.L. Reis, S. Hemmi, J. Pavlovic, R.M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science. 264: 1918-1921 [Medline]. |
40. | Weck, K.E., A.J. Dal, Canto, J.D. Gould, A.K. O'Guin, K.A. Roth, J.E. Saffitz, S.H. Speck, and H.W. Virgin. 1997. Murine gamma-herpesvirus 68 causes large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat. Med. 3: 1346-1353 [Medline]. |
41. | Heise, M.T., J.L. Pollock, S.K. Bromley, M.L. Barkon, and H.W. Virgin. 1998. Murine cytomegalovirus infection suppresses interferon-gamma-mediated MHC class II expression on macrophages: the role of type I interferon. Virology. 241: 331-344 [Medline]. |
42. |
MacDonald, M.R.,
X.Y. Li,
R.M. Stenberg,
A.E. Campbell, and
H.W. Virgin IV..
1998.
Mucosal and parenteral vaccination
against acute and latent murine cytomegalovirus (MCMV)
infection using an attenuated MCMV mutant.
J. Virol.
72:
442-451
|
43. | Armas, J.C.G., C.S. Morello, L.D. Cranmer, and D.H. Spector. 1996. DNA immunization confers protection against murine cytomegalovirus infection. J. Virol. 70: 7921-7928 [Abstract]. |
44. | Jordan, M.C., and V.L. Mar. 1982. Spontaneous activation of latent cytomegalovirus from murine spleen explants: Role of lymphocytes and macrophages in release and replication of virus. J. Clin. Invest. 70: 762-768 [Medline]. |
45. | Wise, T.G., J.E. Manischewitz, G.V. Quinnan, G.S. Aulakh, and F.A. Ennis. 1979. Latent cytomegalovirus infection of Balb/c mouse spleens detected by an explant culture technique. J. Gen. Virol. 44: 551-556 [Abstract]. |
46. | Cantin, E.M., D.R. Hinton, J. Chen, and H. Oppenshaw. 1995. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J. Virol. 69: 4898-4905 [Abstract]. |
47. | Halford, W.P., B.M. Gebhardt, and D.J. Carr. 1996. Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1. J. Immunol. 157: 3542-3549 [Abstract]. |
48. |
Heise, M.T.,
M. Connick, and
H.W. Virgin IV..
1998.
Murine cytomegalovirus inhibits interferon ![]() |
49. |
Miller, D.M.,
B.M. Rahill,
J.M. Boss,
M.D. Lairmore,
J.E. Durbin,
J.W. Waldman, and
D.D. Sedmak.
1998.
Human
cytomegalovirus inhibits major histocompatibility complex
class II expression by disruption of the Jak/Stat pathway.
J.
Exp. Med.
187:
675-683
|
50. | Virgin, H.W., P. Latreille, P. Wamsley, K. Hallsworth, K.E. Weck, A.J. Dal, Canto, and S.H. Speck. 1997. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71: 5894-5904 [Abstract]. |
51. | Rawlinson, W.D., H.E. Farrell, and B.G. Barrell. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70: 8833-8849 [Abstract]. |
52. |
Koffron, A.J.,
M. Hummel,
B.K. Patterson,
S. Yan,
D.B. Kaufman,
J.P. Fryer,
F.P. Stuart, and
M.I. Abecassis.
1998.
Cellular localization of latent murine cytomegalovirus.
J. Virol.
72:
95-103
|
53. | Hansson, G.K., M. Hellstrand, L. Rymo, L. Rubbia, and G. Gabbiani. 1989. Interferon-gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170: 1595-1608 [Abstract]. |
54. | Geng, Y.-J., and G.K. Hansson. 1992. Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J. Clin. Invest. 89: 1322-1330 [Medline]. |